AllSci News
BioNTech advances mRNA therapeutic HIV vaccine into randomized Phase I/II trial
BioNTech has registered a randomized, placebo-controlled Phase I/II clinical trial of BNT168, an mRNA vaccine designed to elicit HIV-specific immune...
Arbutus escalates LNP patent battle against Pfizer and BioNTech across North America and EU
Arbutus Biopharma and its exclusive licensee Genevant Sciences have expanded their patent campaign against Pfizer and BioNTech, filing new infringement lawsuits in…
Argenx taps Chai Discovery's AI for de novo antibody engineering in immunology
San Francisco-based Chai Discovery has entered a collaboration agreement with argenx (Euronext & Nasdaq: ARGX) granting the immunology company early access...
Shionogi seeking to expand Fetroja use into pediatric settings
Japan-based Shionogi & Co., Ltd. said the US FDA has accepted a Supplemental New Drug Application (sNDA) for cefiderocol (Fetroja), seeking to extend the...
Cardiff Oncology raises USD 10m ahead of regulatory push for onvansertib in RAS-mutated colorectal cancer
San Diego-based Cardiff Oncology, Inc. (Nasdaq: CRDF) announced a USD 10 million registered direct offering on July 15, 2026, with proceeds directed toward...
Merck's Keytruda becomes first PD-1 inhibitor to beat chemotherapy in frontline dMMR endometrial cancer
Merck (NYSE: MRK) reported that pembrolizumab (Keytruda) monotherapy met its primary progression-free survival endpoint in the Phase III KEYNOTE-C93 trial,...
Allogene achieves first durable remissions with allogeneic CAR-T in solid tumors
Allogene Therapeutics (Nasdaq: ALLO) has published complete Phase I data from its TRAVERSE trial in the Journal of Clinical Oncology, reporting the first...
Ractigen's siRNA therapy RAG-17 shows deep SOD1 knockdown in first-in-human ALS trial
China-based Ractigen Therapeutics has published Phase I clinical data for RAG-17, an intrathecally delivered siRNA targeting SOD1 mRNA in patients with...
Angelini closes Catalyst Pharma buy for USD 4.1b, gains US foothold in rare neuromuscular disease
Angelini Pharma S.p.A. has completed its acquisition of Coral Gables, Florida-based Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) in a transaction valued at...
Hemispheric emerges from stealth to launch Descartes neuroAI brain decoding model
Israel-based Hemispheric has emerged from stealth with USD 52 million in early-stage funding to commercialize a large-scale AI platform designed to generate...
Lilly bets USD 3.8b on psychedelic medicine with AtaiBeckley acquisition
Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biotechnology company developing...
United Labs collects USD 13.5m milestone as Novo Nordisk advances UBT251 into Phase II
The United Laboratories International Holdings Limited (HKEX: 03933) has received a USD 13.5 million milestone payment from Novo Nordisk, triggered by the...
Merck wins US FDA approval for first oral PCSK9 inhibitor
The US FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, for adults with hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH), a milestone…
Novo Nordisk picks up Europe’s first approval for oral GLP-1 in weight management
The European Commission has granted marketing authorization for Wegovy pill (once-daily oral semaglutide 25 mg), making Denmark-based Novo Nordisk the first company…
Braveheart Bio files for Nasdaq IPO to fund Phase III cardiac myosin inhibitor in HCM
Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage cardiovascular company seeking to enter a hypertrophic cardiomyopathy (HCM) market already served by...
The AllSci Brief
Systematic R&D and deal news. Daily.